항우울제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antidepressants Market size is expected to reach USD 47.40 Billion in 2034 from USD 23.87 Billion (2025) growing at a CAGR of 7.92% during 2026-2034.

The global antidepressants market is witnessing consistent growth due to the increasing prevalence of mental health disorders such as depression and anxiety. Changing lifestyles, rising stress levels, and growing awareness about mental health issues are contributing to the demand for effective antidepressant medications. Healthcare providers are increasingly recognizing the importance of early diagnosis and treatment of mental health conditions.

A major driver of the market is the growing acceptance of mental health treatment and the expansion of mental healthcare services worldwide. Pharmaceutical companies are focusing on developing innovative antidepressant drugs with improved safety profiles and faster therapeutic effects. In addition, the expansion of telehealth and online mental health platforms is improving patient access to diagnosis and treatment.

In the future, the antidepressants market is expected to grow as mental health awareness continues to increase globally. Advances in neuroscience research and personalized medicine approaches may lead to the development of more targeted treatment options. With rising healthcare investments and expanding mental health support systems, the market is likely to experience sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Atypical Antidepressants
• Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
• Monoamine Oxidase Inhibitors (MAOIs)
• Other Drug Classes

By Application

• Major Depressive Disorder
• Generalized Anxiety Disorder
• Obsessive-Compulsive Disorder
• Panic Disorder
• Other Applications

By Route of Administration

• Oral
• Injectable
• Nasal
• Transdermal

By Medication Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• BristolMyers Squibb, Eli Lilly and Company, GlaxoSmithKline, IntraCellular Therapies, Janssen Pharmaceuticals, NV Organon, Novartis, Opko Health, Otsuka Pharmaceutical, Patheon, Pfizer, Sandoz
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIDEPRESSANTS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Selective Serotonin Reuptake Inhibitors (SSRIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tricyclic Antidepressants (TCAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Atypical Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Norepinephrine-Dopamine Reuptake Inhibitor (NDRI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Monoamine Oxidase Inhibitors (MAOIs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIDEPRESSANTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Major Depressive Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Generalized Anxiety Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Obsessive-Compulsive Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Panic Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIDEPRESSANTS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Nasal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Transdermal Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIDEPRESSANTS MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Medication Type
• 7.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIDEPRESSANTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIDEPRESSANTS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Application
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Medication Type
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Application
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Medication Type
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Application
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Medication Type
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Application
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Medication Type
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Application
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Medication Type
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIDEPRESSANTS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Bristol-Myers Squibb
  • 11.2.2 Eli Lilly And Company
  • 11.2.3 GlaxoSmithKline
  • 11.2.4 Intra-Cellular Therapies
  • 11.2.5 Janssen Pharmaceuticals
  • 11.2.6 N.V. Organon
  • 11.2.7 Novartis
  • 11.2.8 Opko Health
  • 11.2.9 Otsuka Pharmaceutical
  • 11.2.10 Patheon
  • 11.2.11 Pfizer
  • 11.2.12 Sandoz